These 2 ASX shares have been under severe pressure lately. CSL Ltd (ASX: CSL) has lost 43% in value over 12 months, while REA Group Ltd (ASX: REA) hasn't fared much better with a 33% loss in the same period.
It's not often investors get the chance to pick up two premium ASX shares at such a steep discount.
Image source: Getty Images
CSL: Deep moat in life-saving medicines
CSL still sits among the world's biotech heavyweights with a deep moat built on plasma-derived therapies, vaccines, and specialty treatments. Its global scale and entrenched position in life-saving medicines give it powerful pricing power and recurring revenue streams in markets that are hard for newcomers to crack.
Massive investment in R&D and strategic partnerships continues to feed its long-term pipeline, while diversified units like Behring, Seqirus, and Vifor spread risk across therapeutic areas.
But it's not all smooth sailing for the ASX biotech share. Recent half-year results disappointed with earnings declines and leadership turmoil dragging sentiment. Competitive pressures, particularly in haemophilia and vaccines, also highlight execution risks.
Concentrated manufacturing capacity and dependence on plasma supply add operational vulnerabilities, and regulatory shifts or reimbursement changes can hit hard. Premium valuation also means the ASX share is sensitive to expectations.
Despite short-term volatility, there's a value case emerging. The stock has pulled back sharply from peak levels, and management is leaning into cost discipline, buybacks, and refocusing on core strengths.
Ageing populations and rising chronic diseases are long-term tailwinds for plasma therapies and specialist medicines. After the recent share price reset, investors may have a rare chance to buy a world-class biotech at a more reasonable valuation.
If second-half earnings stabilise and growth catalysts return, sentiment could turn quickly.
Morgans recently retained a buy recommendation. However, it did trim forecasts and lowered its price target to $241.34, which still represents a massive 64% upside from current levels.
REA Group: Market leader with sticky revenue
In digital real estate, scale wins. REA has it in spades. This ASX share owns realestate.com.au, Australia's dominant online property marketplace. It also has realcommercial.com.au, PropTrack, flatmates.com.au, Mortgage Choice, and Indian and US real estate portal businesses.
The business generates powerful cash flow and consistently flexes its pricing power. Agents pay up for depth products, premium listings, and data insights because that's where the buyers are. Even when listings soften, the ASX share has historically lifted yield per listing to keep revenue climbing.
The latest quarterly numbers reinforced the point: revenue and EBITDA rose, driven more by smarter pricing and product mix than raw volume. That's what quality platforms do. REA's moat is obvious: market leadership, network effects, and sticky, recurring agent services.
The ASX share has come under pressure as listing volumes softened, market sentiment turned cautious, and AI disruption fears crept in. But its grip on Australian online property advertising hasn't loosened.
The company still commands pricing power, strong brand equity, and high-margin digital economics.
For long-term investors, a 33% pullback in a category leader doesn't automatically signal trouble. It can signal an opportunity. Most brokers seem to think so.
Following the half-year results, Bell Potter has maintained its buy rating on the ASX share but trimmed its price target to $211 from $244. With the shares currently trading at $159.02, that implies potential upside of nearly 33% over the next 12 months.
